c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation
Duan, Y., Chen, L., Chen, Y., Fan, X.G.(2014) Plos One 9: e106225-e106225
- PubMed: 25197973 
- DOI: 10.1371/journal.pone.0106225
- PubMed Abstract: 
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase. There is no s ...